Drugs / rF-PSA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00045227 | Aug 2002 → Oct 2007 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005916 | Jun 2000 → Dec 2005 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rF-PSA | “sequential booster vaccinations with recombinant fowlpox virus (rF-) containing the PSA gene (rF-PSA).” PMID 16489082 ↗ Feb 2006 |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00045227 ↗ |
| Modality | Vaccine | “The vaccine regimen will be composed of (1) a recombinant vaccinia virus that expresses the Prostate Specific Antigen gene (rV-PSA), admixed with (2) a recombinant vaccinia...” NCT00005916 ↗ |